Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study.
Adult
Aged
Aged, 80 and over
Betacoronavirus
COVID-19
Cohort Studies
Coronavirus Infections
/ complications
Female
Humans
Italy
Male
Middle Aged
Olfaction Disorders
/ diagnosis
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
Sensory Thresholds
Severity of Illness Index
Taste Disorders
/ diagnosis
Young Adult
COVID-19
ageusia
anosmia
smell
taste
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
30
04
2020
accepted:
04
05
2020
pubmed:
22
5
2020
medline:
21
7
2020
entrez:
22
5
2020
Statut:
ppublish
Résumé
Objective data on chemosensitive disorders during COVID-19 are lacking in the Literature. Multicenter cohort study that involved four Italian hospitals. Three hundred and forty-five COVID-19 patients underwent objective chemosensitive evaluation. Chemosensitive disorders self-reported by 256 patients (74.2%) but the 30.1% of the 89 patients who did not report dysfunctions proved objectively hyposmic. Twenty-five percentage of patients were seen serious long-lasting complaints. All asymptomatic patients had a slight lowering of the olfactory threshold. No significant correlations were found between the presence and severity of chemosensitive disorders and the severity of the clinical course. On the contrary, there is a significant correlation between the duration of the olfactory and gustatory symptoms and the development of severe COVID-19. Patients under-report the frequency of chemosensitive disorders. Contrary to recent reports, such objective testing refutes the proposal that the presence of olfactory and gustatory dysfunction may predict a milder course, but instead suggests that those with more severe disease neglect such symptoms in the setting of severe respiratory disease.
Sections du résumé
BACKGROUND
BACKGROUND
Objective data on chemosensitive disorders during COVID-19 are lacking in the Literature.
METHODS
METHODS
Multicenter cohort study that involved four Italian hospitals. Three hundred and forty-five COVID-19 patients underwent objective chemosensitive evaluation.
RESULTS
RESULTS
Chemosensitive disorders self-reported by 256 patients (74.2%) but the 30.1% of the 89 patients who did not report dysfunctions proved objectively hyposmic. Twenty-five percentage of patients were seen serious long-lasting complaints. All asymptomatic patients had a slight lowering of the olfactory threshold. No significant correlations were found between the presence and severity of chemosensitive disorders and the severity of the clinical course. On the contrary, there is a significant correlation between the duration of the olfactory and gustatory symptoms and the development of severe COVID-19.
CONCLUSIONS
CONCLUSIONS
Patients under-report the frequency of chemosensitive disorders. Contrary to recent reports, such objective testing refutes the proposal that the presence of olfactory and gustatory dysfunction may predict a milder course, but instead suggests that those with more severe disease neglect such symptoms in the setting of severe respiratory disease.
Identifiants
pubmed: 32437022
doi: 10.1002/hed.26269
pmc: PMC7280583
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1560-1569Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Med Mal Infect. 2020 Aug;50(5):436-439
pubmed: 32305563
Head Neck. 2020 Jun;42(6):1252-1258
pubmed: 32342566
Ecancermedicalscience. 2020 Apr 03;14:ed98
pubmed: 32269598
JAMA. 2020 May 26;323(20):2089-2090
pubmed: 32320008
Rhinology. 2020 Jun 1;58(3):295-298
pubmed: 32277751
Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950
pubmed: 32301284
Head Neck. 2020 Jul;42(7):1560-1569
pubmed: 32437022
Indian J Otolaryngol Head Neck Surg. 2014 Jan;66(1):31-4
pubmed: 24605298
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
J Neurocytol. 1979 Feb;8(1):1-18
pubmed: 438867
Sci Adv. 2020 Jul 31;6(31):
pubmed: 32937591
Lancet Infect Dis. 2020 Sep;20(9):1015-1016
pubmed: 32304629
Laryngoscope. 1988 Jan;98(1):83-8
pubmed: 3336267
Acta Pol Pharm. 2012 Jan-Feb;69(1):121-7
pubmed: 22574515
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Br J Oral Maxillofac Surg. 2020 Jun;58(5):615-616
pubmed: 32362452
Head Neck. 2018 Mar;40(3):467-474
pubmed: 29130554
Exp Neurol. 1992 Jan;115(1):50-4
pubmed: 1370222
Head Neck. 2020 Jul;42(7):1570-1576
pubmed: 32357379
Int Forum Allergy Rhinol. 2020 Sep;10(9):1103-1104
pubmed: 32342636
Laryngoscope. 2020 Jul;130(7):1787
pubmed: 32237238
BMJ. 2020 Apr 2;369:m1375
pubmed: 32241884
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2389-2390
pubmed: 32328771
Int Forum Allergy Rhinol. 2020 Jul;10(7):821-831
pubmed: 32329222
Handb Clin Neurol. 2019;164:229-246
pubmed: 31604550